Structures by: Poirier M.
Total: 8
6-methyl-2-(3-methyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)pyrimidin-4(3H)-one
C13H16N4O
RSC Medicinal Chemistry (2020)
a=8.1640(3)Å b=8.5511(4)Å c=19.8770(7)Å
α=93.396(3)° β=99.154(3)° γ=117.195(4)°
2-(3-ethyl-4,5,6,7-tetrahydro-2H-indazol-2-yl)-6-methylpyrimidin-4(3H)-one
C14H18N4O
RSC Medicinal Chemistry (2020)
a=18.8002(2)Å b=9.62410(10)Å c=14.3730(2)Å
α=90° β=90° γ=90°
6-ethyl-4-hydroxy-2-(3-methyl-5-oxo-2,5-dihydro-1H-pyrazol-1-yl)pyrimidin-1-ium
Cl,C10H13N4O2,H2O
RSC Medicinal Chemistry (2020)
a=8.66205(5)Å b=14.39226(6)Å c=9.94738(4)Å
α=90° β=90.8062(4)° γ=90°
2-(exo-mercapto)-2'-thioxo-(1R, 1R')-3-(exo),3'-(exo)-bibornanyl
C20H32S2
Acta Crystallographica Section C (1997) 53, 3 387-391
a=12.092(4)Å b=20.540(2)Å c=7.772(2)Å
α=90.00° β=90.00° γ=90.00°
2-dehydro-2,2'-(exo)-epidithio-3,3'-bibornane
C20H30S2
Acta Crystallographica Section C (1997) 53, 3 387-391
a=11.353(4)Å b=22.289(2)Å c=7.468(1)Å
α=90.00° β=90.00° γ=90.00°
2-(endo),2'-(exo)-epidithio-3,3'-bibornanylidene
C20H30S2
Acta Crystallographica Section C (1997) 53, 3 387-391
a=12.335(1)Å b=21.044(2)Å c=7.293(2)Å
α=90.00° β=90.00° γ=90.00°
C11H14O4S
C11H14O4S
Journal of Organic Chemistry (2008) 73, 7457-7466
a=7.5897(8)Å b=9.957(6)Å c=15.340(3)Å
α=90° β=99.483(11)° γ=90°
C12H14O6S
C12H14O6S
Journal of Organic Chemistry (2008) 73, 7457-7466
a=10.055(7)Å b=12.797(9)Å c=10.247(6)Å
α=90° β=92.85(6)° γ=90°